181 related articles for article (PubMed ID: 11861816)
1. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Yamaguchi H; Yano I; Saito H; Inui K
J Pharmacol Exp Ther; 2002 Mar; 300(3):1063-9. PubMed ID: 11861816
[TBL] [Abstract][Full Text] [Related]
2. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
Yamaguchi H; Yano I; Hashimoto Y; Inui KI
J Pharmacol Exp Ther; 2000 Oct; 295(1):360-6. PubMed ID: 10992002
[TBL] [Abstract][Full Text] [Related]
3. Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
Yamaguchi H; Yano I; Saito H; Inui K
Pharm Res; 2004 Feb; 21(2):330-8. PubMed ID: 15032316
[TBL] [Abstract][Full Text] [Related]
4. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.
Naruhashi K; Tamai I; Inoue N; Muraoka H; Sai Y; Suzuki N; Tsuji A
J Pharm Pharmacol; 2001 May; 53(5):699-709. PubMed ID: 11370709
[TBL] [Abstract][Full Text] [Related]
5. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney.
Ito T; Yano I; Masuda S; Hashimoto Y; Inui K
Pharm Res; 1999 Apr; 16(4):534-9. PubMed ID: 10227708
[TBL] [Abstract][Full Text] [Related]
6. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.
Yamaguchi H; Yano I; Saito H; Inui K
Eur J Pharmacol; 2001 Nov; 431(3):297-303. PubMed ID: 11730721
[TBL] [Abstract][Full Text] [Related]
7. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
Tamai I; Yamashita J; Kido Y; Ohnari A; Sai Y; Shima Y; Naruhashi K; Koizumi S; Tsuji A
J Pharmacol Exp Ther; 2000 Oct; 295(1):146-52. PubMed ID: 10991972
[TBL] [Abstract][Full Text] [Related]
8. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.
Sikri V; Pal D; Jain R; Kalyani D; Mitra AK
Am J Ther; 2004; 11(6):433-42. PubMed ID: 15543082
[TBL] [Abstract][Full Text] [Related]
9. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats.
Naruhashi K; Tamai I; Inoue N; Muraoka H; Sai Y; Suzuki N; Tsuji A
Antimicrob Agents Chemother; 2002 Feb; 46(2):344-9. PubMed ID: 11796340
[TBL] [Abstract][Full Text] [Related]
10. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones.
Ando T; Kusuhara H; Merino G; Alvarez AI; Schinkel AH; Sugiyama Y
Drug Metab Dispos; 2007 Oct; 35(10):1873-9. PubMed ID: 17639028
[TBL] [Abstract][Full Text] [Related]
11. Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells.
Lowes S; Simmons NL
Br J Pharmacol; 2002 Mar; 135(5):1263-75. PubMed ID: 11877335
[TBL] [Abstract][Full Text] [Related]
12. Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
Zhao YL; Cai SH; Wang L; Kitaichi K; Tatsumi Y; Nadai M; Yoshizumi H; Takagi K; Takagi K; Hasegawa T
Clin Exp Pharmacol Physiol; 2002 Mar; 29(3):167-72. PubMed ID: 11906478
[TBL] [Abstract][Full Text] [Related]
13. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin.
Sugie M; Asakura E; Zhao YL; Torita S; Nadai M; Baba K; Kitaichi K; Takagi K; Takagi K; Hasegawa T
Antimicrob Agents Chemother; 2004 Mar; 48(3):809-14. PubMed ID: 14982769
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.
de Lange EC; Marchand S; van den Berg D; van der Sandt IC; de Boer AG; Delon A; Bouquet S; Couet W
Eur J Pharm Sci; 2000 Dec; 12(2):85-93. PubMed ID: 11102735
[TBL] [Abstract][Full Text] [Related]
15. The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671.
Beaumont K; Harper A; Smith DA; Bennett J
Eur J Pharm Sci; 2000 Nov; 12(1):41-50. PubMed ID: 11121732
[TBL] [Abstract][Full Text] [Related]
16. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice.
Jin M; Shimada T; Yokogawa K; Nomura M; Ishizaki J; Piao Y; Kato Y; Tsuji A; Miyamoto K
Biochem Pharmacol; 2006 Oct; 72(8):1042-50. PubMed ID: 16939683
[TBL] [Abstract][Full Text] [Related]
17. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats.
Hsiu SL; Hou YC; Wang YH; Tsao CW; Su SF; Chao PD
Life Sci; 2002 Dec; 72(3):227-35. PubMed ID: 12427482
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.
Efthymiopoulos C; Bramer SL; Maroli A
Clin Pharmacokinet; 1997; 33 Suppl 1():1-8. PubMed ID: 9433650
[TBL] [Abstract][Full Text] [Related]
20. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone.
Jin M; Shimada T; Yokogawa K; Nomura M; Kato Y; Tsuji A; Miyamoto K
Int J Pharm; 2006 Feb; 309(1-2):81-6. PubMed ID: 16384676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
